Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 119 entries
Sorted by: Best Match Show Resources per page
Correction: Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer.

PloS one

Juzėnas S, Saltenienė V, Kupcinskas J, Link A, Kiudelis G, Jonaitis L, Jarmalaite S, Kupcinskas L, Malfertheiner P, Skieceviciene J.
PMID: 26266534
PLoS One. 2015 Aug 12;10(8):e0135762. doi: 10.1371/journal.pone.0135762. eCollection 2015.

No abstract available.

Cite
Juzėnas S, Saltenienė V, Kupcinskas J, et al. Correction: Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer. PLoS One. 2015;10(8):e0135762doi: 10.1371/journal.pone.0135762.
Juzėnas, S., Saltenienė, V., Kupcinskas, J., Link, A., Kiudelis, G., Jonaitis, L., Jarmalaite, S., Kupcinskas, L., Malfertheiner, P., & Skieceviciene, J. (2015). Correction: Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer. PloS one, 10(8), e0135762. https://doi.org/10.1371/journal.pone.0135762
Juzėnas, Simonas, et al. "Correction: Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer." PloS one vol. 10,8 (2015): e0135762. doi: https://doi.org/10.1371/journal.pone.0135762
Juzėnas S, Saltenienė V, Kupcinskas J, Link A, Kiudelis G, Jonaitis L, Jarmalaite S, Kupcinskas L, Malfertheiner P, Skieceviciene J. Correction: Analysis of Deregulated microRNAs and Their Target Genes in Gastric Cancer. PLoS One. 2015 Aug 12;10(8):e0135762. doi: 10.1371/journal.pone.0135762. eCollection 2015. PMID: 26266534; PMCID: PMC4534416.
Copy Download .nbib Format: NLM
Nutrition in Patients with Gastric Cancer: An Update.

Gastrointestinal tumors

Rosania R, Chiapponi C, Malfertheiner P, Venerito M.
PMID: 27403412
Gastrointest Tumors. 2016 May;2(4):178-87. doi: 10.1159/000445188. Epub 2016 Apr 13.

BACKGROUND: Nutritional management of patients with gastric cancer (GC) represents a challenge.SUMMARY: This review provides an overview of the present evidence on nutritional support in patients with GC undergoing surgery as well as in those with advanced disease.KEY MESSAGE:...

Cite
Rosania R, Chiapponi C, Malfertheiner P, et al. Nutrition in Patients with Gastric Cancer: An Update. Gastrointest Tumors. 2016;2(4):178-87doi: 10.1159/000445188.
Rosania, R., Chiapponi, C., Malfertheiner, P., & Venerito, M. (2016). Nutrition in Patients with Gastric Cancer: An Update. Gastrointestinal tumors, 2(4), 178-87. https://doi.org/10.1159/000445188
Rosania, Rosa, et al. "Nutrition in Patients with Gastric Cancer: An Update." Gastrointestinal tumors vol. 2,4 (2016): 178-87. doi: https://doi.org/10.1159/000445188
Rosania R, Chiapponi C, Malfertheiner P, Venerito M. Nutrition in Patients with Gastric Cancer: An Update. Gastrointest Tumors. 2016 May;2(4):178-87. doi: 10.1159/000445188. Epub 2016 Apr 13. PMID: 27403412; PMCID: PMC4924460.
Copy Download .nbib Format: NLM
Nutrition and Hepatocellular Cancer.

Gastrointestinal tumors

Schütte K, Schulz C, Malfertheiner P.
PMID: 27403413
Gastrointest Tumors. 2016 May;2(4):188-94. doi: 10.1159/000441822. Epub 2015 Nov 18.

BACKGROUND: Hepatocellular carcinoma (HCC) significantly contributes to the global burden of cancer. Liver cancer is the third most frequent cause of cancer-related death with HCC representing more than 90% of primary liver cancers. The majority of patients are not...

Cite
Schütte K, Schulz C, Malfertheiner P. Nutrition and Hepatocellular Cancer. Gastrointest Tumors. 2015;2(4):188-94doi: 10.1159/000441822.
Schütte, K., Schulz, C., & Malfertheiner, P. (2016). Nutrition and Hepatocellular Cancer. Gastrointestinal tumors, 2(4), 188-94. https://doi.org/10.1159/000441822
Schütte, Kerstin, et al. "Nutrition and Hepatocellular Cancer." Gastrointestinal tumors vol. 2,4 (2016): 188-94. doi: https://doi.org/10.1159/000441822
Schütte K, Schulz C, Malfertheiner P. Nutrition and Hepatocellular Cancer. Gastrointest Tumors. 2016 May;2(4):188-94. doi: 10.1159/000441822. Epub 2015 Nov 18. PMID: 27403413; PMCID: PMC4924450.
Copy Download .nbib Format: NLM
[S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease].

Zeitschrift fur Gastroenterologie

Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann CJ, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M.
PMID: 27168132
Z Gastroenterol. 2016 Apr;54(4):1. doi: 10.1055/s-0035-1567086. Epub 2016 May 11.

In the line "bismuth-containing quadruple therapy" of Table 7 (p 342), in the column "dosage" incorrectly at the three antibiotics respectively 1-1-1-1. The correct is: 3-3-3-3.

Cite
Fischbach W, Malfertheiner P, Lynen Jansen P, et al. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Z Gastroenterol. 2016;54(4):1doi: 10.1055/s-0035-1567086.
Fischbach, W., Malfertheiner, P., Lynen Jansen, P., Bolten, W., Bornschein, J., Buderus, S., Glocker, E., Hoffmann, C. J., Koletzko, S., Labenz, J., Mayerle, J., Miehlke, S., Mössner, J., Peitz, U., Prinz, C., Selgrad, M., Suerbaum, S., Venerito, M., Vieth, M. (2016). S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Zeitschrift fur Gastroenterologie, 54(4), 1. https://doi.org/10.1055/s-0035-1567086
Fischbach, W, et al. "S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit." [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Zeitschrift fur Gastroenterologie vol. 54,4 (2016): 1. doi: https://doi.org/10.1055/s-0035-1567086
Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann CJ, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Z Gastroenterol. 2016 Apr;54(4):1. doi: 10.1055/s-0035-1567086. Epub 2016 May 11. German. PMID: 27168132.
Copy Download .nbib Format: NLM
Metastatic Disease in the Stomach.

Gastrointestinal tumors

Weigt J, Malfertheiner P.
PMID: 26674003
Gastrointest Tumors. 2015 Sep;2(2):61-4. doi: 10.1159/000431304. Epub 2015 Jun 12.

BACKGROUND: Gastric metastases are rare and represent a late and progressed stage of malignant disease. This review highlights epidemiological, clinical and endoscopic findings as well as therapeutic strategies for metastatic disease of the stomach.SUMMARY: The clinical presentation of gastric...

Cite
Weigt J, Malfertheiner P. Metastatic Disease in the Stomach. Gastrointest Tumors. 2015;2(2):61-4doi: 10.1159/000431304.
Weigt, J., & Malfertheiner, P. (2015). Metastatic Disease in the Stomach. Gastrointestinal tumors, 2(2), 61-4. https://doi.org/10.1159/000431304
Weigt, Joche, and Malfertheiner, Pete. "Metastatic Disease in the Stomach." Gastrointestinal tumors vol. 2,2 (2015): 61-4. doi: https://doi.org/10.1159/000431304
Weigt J, Malfertheiner P. Metastatic Disease in the Stomach. Gastrointest Tumors. 2015 Sep;2(2):61-4. doi: 10.1159/000431304. Epub 2015 Jun 12. PMID: 26674003; PMCID: PMC4668793.
Copy Download .nbib Format: NLM
Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease.

Liver cancer

Schütte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, Malfertheiner P.
PMID: 24159590
Liver Cancer. 2012 Nov;1(3):257-66. doi: 10.1159/000343840.

BACKGROUND: Adherence to surveillance recommendations for patients at risk of developing hepatocellular carcinoma (HCC) is influenced by several factors, including the etiology of chronic liver disease.AIM: The aim of this study was to analyze whether tumor stage at diagnosis...

Cite
Schütte K, Bornschein J, Kahl S, et al. Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer. 2012;1(3):257-66doi: 10.1159/000343840.
Schütte, K., Bornschein, J., Kahl, S., Seidensticker, R., Arend, J., Ricke, J., & Malfertheiner, P. (2012). Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver cancer, 1(3), 257-66. https://doi.org/10.1159/000343840
Schütte, Kerstin, et al. "Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease." Liver cancer vol. 1,3 (2012): 257-66. doi: https://doi.org/10.1159/000343840
Schütte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, Malfertheiner P. Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer. 2012 Nov;1(3):257-66. doi: 10.1159/000343840. PMID: 24159590; PMCID: PMC3760467.
Copy Download .nbib Format: NLM
Inflammatory Myofibroblastic Tumor of the Pancreatic Head: An Unusual Cause of Recurrent Acute Pancreatitis - Case Presentation of a Palliative Approach after Failed Resection and Review of the Literature.

Case reports in gastroenterology

Schütte K, Kandulski A, Kuester D, Meyer F, Wieners G, Schulz HU, Malfertheiner P.
PMID: 21113286
Case Rep Gastroenterol. 2010 Oct 18;4(3):443-451. doi: 10.1159/000320953.

Inflammatory myofibroblastic tumors (IMTs) are a rare cause of echo-poor pancreatic head enlargement. Histologically, IMTs are characterized by spindle-shaped myofibroblasts or fibroblasts accompanied by a mixed immune cell infiltration. The most common localizations of IMTs have been reported in...

Cite
Schütte K, Kandulski A, Kuester D, et al. Inflammatory Myofibroblastic Tumor of the Pancreatic Head: An Unusual Cause of Recurrent Acute Pancreatitis - Case Presentation of a Palliative Approach after Failed Resection and Review of the Literature. Case Rep Gastroenterol. 2010;4(3):443-451doi: 10.1159/000320953.
Schütte, K., Kandulski, A., Kuester, D., Meyer, F., Wieners, G., Schulz, H. U., & Malfertheiner, P. (2010). Inflammatory Myofibroblastic Tumor of the Pancreatic Head: An Unusual Cause of Recurrent Acute Pancreatitis - Case Presentation of a Palliative Approach after Failed Resection and Review of the Literature. Case reports in gastroenterology, 4(3), 443-451. https://doi.org/10.1159/000320953
Schütte, Kerstin, et al. "Inflammatory Myofibroblastic Tumor of the Pancreatic Head: An Unusual Cause of Recurrent Acute Pancreatitis - Case Presentation of a Palliative Approach after Failed Resection and Review of the Literature." Case reports in gastroenterology vol. 4,3 (2010): 443-451. doi: https://doi.org/10.1159/000320953
Schütte K, Kandulski A, Kuester D, Meyer F, Wieners G, Schulz HU, Malfertheiner P. Inflammatory Myofibroblastic Tumor of the Pancreatic Head: An Unusual Cause of Recurrent Acute Pancreatitis - Case Presentation of a Palliative Approach after Failed Resection and Review of the Literature. Case Rep Gastroenterol. 2010 Oct 18;4(3):443-451. doi: 10.1159/000320953. PMID: 21113286; PMCID: PMC2988857.
Copy Download .nbib Format: NLM
Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model.

Gut pathogens

Jacobi CA, Grundler S, Hsieh CJ, Frick JS, Adam P, Lamprecht G, Autenrieth IB, Gregor M, Malfertheiner P.
PMID: 22862922
Gut Pathog. 2012 Aug 03;4(1):8. doi: 10.1186/1757-4749-4-8.

BACKGROUND: "Quorum sensing" (QS) is the phenomenon which allows single bacterial cells to measure the concentration of bacterial signal molecules. Two principle different QS systems are known, the Autoinducer 1 system (AI-1) for the intraspecies communication using different Acyl-homoserine...

Cite
Jacobi CA, Grundler S, Hsieh CJ, et al. Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model. Gut Pathog. 2012;4(1):8doi: 10.1186/1757-4749-4-8.
Jacobi, C. A., Grundler, S., Hsieh, C. J., Frick, J. S., Adam, P., Lamprecht, G., Autenrieth, I. B., Gregor, M., & Malfertheiner, P. (2012). Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model. Gut pathogens, 4(1), 8. https://doi.org/10.1186/1757-4749-4-8
Jacobi, Christoph A, et al. "Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model." Gut pathogens vol. 4,1 (2012): 8. doi: https://doi.org/10.1186/1757-4749-4-8
Jacobi CA, Grundler S, Hsieh CJ, Frick JS, Adam P, Lamprecht G, Autenrieth IB, Gregor M, Malfertheiner P. Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model. Gut Pathog. 2012 Aug 03;4(1):8. doi: 10.1186/1757-4749-4-8. PMID: 22862922; PMCID: PMC3480846.
Copy Download .nbib Format: NLM
Upregulation of leukotriene receptors in gastric cancer.

Cancers

Venerito M, Kuester D, Harms C, Schubert D, Wex T, Malfertheiner P.
PMID: 24212950
Cancers (Basel). 2011 Aug 08;3(3):3156-68. doi: 10.3390/cancers3033156.

BACKGROUND: Leukotrienes (LT) mediate allergic and inflammatory processes. Previously, we identified significant changes in the expression pattern of LT receptors in the gastric mucosa after eradication of Helicobacter pylori infection. The aim of the present study was to evaluate...

Cite
Venerito M, Kuester D, Harms C, et al. Upregulation of leukotriene receptors in gastric cancer. Cancers (Basel). 2011;3(3):3156-68doi: 10.3390/cancers3033156.
Venerito, M., Kuester, D., Harms, C., Schubert, D., Wex, T., & Malfertheiner, P. (2011). Upregulation of leukotriene receptors in gastric cancer. Cancers, 3(3), 3156-68. https://doi.org/10.3390/cancers3033156
Venerito, Marino, et al. "Upregulation of leukotriene receptors in gastric cancer." Cancers vol. 3,3 (2011): 3156-68. doi: https://doi.org/10.3390/cancers3033156
Venerito M, Kuester D, Harms C, Schubert D, Wex T, Malfertheiner P. Upregulation of leukotriene receptors in gastric cancer. Cancers (Basel). 2011 Aug 08;3(3):3156-68. doi: 10.3390/cancers3033156. PMID: 24212950; PMCID: PMC3759191.
Copy Download .nbib Format: NLM
Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit.

Intensive care medicine experimental

Ki KK, Passmore MR, Chan CHH, Malfertheiner MV, Fanning JP, Bouquet M, Millar JE, Fraser JF, Suen JY.
PMID: 31432279
Intensive Care Med Exp. 2019 Aug 20;7(1):51. doi: 10.1186/s40635-019-0264-z.

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is a life-saving modality used to manage cardiopulmonary failure refractory to conventional medical and surgical therapies. Despite advances in ECMO equipment, bleeding and thrombosis remain significant complications. While the flow rate for ECMO support...

Cite
Ki KK, Passmore MR, Chan CHH, et al. Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive Care Med Exp. 2019;7(1):51doi: 10.1186/s40635-019-0264-z.
Ki, K. K., Passmore, M. R., Chan, C. H. H., Malfertheiner, M. V., Fanning, J. P., Bouquet, M., Millar, J. E., Fraser, J. F., & Suen, J. Y. (2019). Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive care medicine experimental, 7(1), 51. https://doi.org/10.1186/s40635-019-0264-z
Ki, Katrina K, et al. "Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit." Intensive care medicine experimental vol. 7,1 (2019): 51. doi: https://doi.org/10.1186/s40635-019-0264-z
Ki KK, Passmore MR, Chan CHH, Malfertheiner MV, Fanning JP, Bouquet M, Millar JE, Fraser JF, Suen JY. Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive Care Med Exp. 2019 Aug 20;7(1):51. doi: 10.1186/s40635-019-0264-z. PMID: 31432279; PMCID: PMC6702240.
Copy Download .nbib Format: NLM
Weaning from veno-venous extracorporeal membrane oxygenation: how I do it.

Journal of thoracic disease

Broman LM, Malfertheiner MV, Montisci A, Pappalardo F.
PMID: 29732188
J Thorac Dis. 2018 Mar;10:S692-S697. doi: 10.21037/jtd.2017.09.95.

Veno-venous extracorporeal membrane oxygenation (VV ECMO) is a rescue treatment for acute respiratory distress syndrome (ARDS) failing protective mechanical ventilation. It temporarily provides proper gas exchange: hypoxia is treated by adjusting the blood flow rate and fraction in spired...

Cite
Broman LM, Malfertheiner MV, Montisci A, et al. Weaning from veno-venous extracorporeal membrane oxygenation: how I do it. J Thorac Dis. 2018;10:S692-S697doi: 10.21037/jtd.2017.09.95.
Broman, L. M., Malfertheiner, M. V., Montisci, A., & Pappalardo, F. (2018). Weaning from veno-venous extracorporeal membrane oxygenation: how I do it. Journal of thoracic disease, 10S692-S697. https://doi.org/10.21037/jtd.2017.09.95
Broman, Lars M, et al. "Weaning from veno-venous extracorporeal membrane oxygenation: how I do it." Journal of thoracic disease vol. 10 (2018): S692-S697. doi: https://doi.org/10.21037/jtd.2017.09.95
Broman LM, Malfertheiner MV, Montisci A, Pappalardo F. Weaning from veno-venous extracorporeal membrane oxygenation: how I do it. J Thorac Dis. 2018 Mar;10:S692-S697. doi: 10.21037/jtd.2017.09.95. PMID: 29732188; PMCID: PMC5911556.
Copy Download .nbib Format: NLM
Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature.

Molecular and clinical oncology

Franck C, Canbay A, Malfertheiner P, Venerito M.
PMID: 29285376
Mol Clin Oncol. 2017 Dec;7(6):1069-1072. doi: 10.3892/mco.2017.1445. Epub 2017 Oct 06.

Perioperative platinum/fluoropyrimidine-based chemotherapy is the therapeutic standard for oesophagogastric cancer (OAC) patients with locoregional disease. The preoperative condition directly affects postoperative prognosis; thus, particularly for elderly patients, a perioperative regimen with a favourable side effect profile is highly desirable....

Cite
Franck C, Canbay A, Malfertheiner P, et al. Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature. Mol Clin Oncol. 2017;7(6):1069-1072doi: 10.3892/mco.2017.1445.
Franck, C., Canbay, A., Malfertheiner, P., & Venerito, M. (2017). Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature. Molecular and clinical oncology, 7(6), 1069-1072. https://doi.org/10.3892/mco.2017.1445
Franck, Caspar, et al. "Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature." Molecular and clinical oncology vol. 7,6 (2017): 1069-1072. doi: https://doi.org/10.3892/mco.2017.1445
Franck C, Canbay A, Malfertheiner P, Venerito M. Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature. Mol Clin Oncol. 2017 Dec;7(6):1069-1072. doi: 10.3892/mco.2017.1445. Epub 2017 Oct 06. PMID: 29285376; PMCID: PMC5740855.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 119 entries